Deep Dive Into Beam Therapeutics Stock: Analyst Perspectives (6 Ratings)
Portfolio Pulse from Benzinga Insights
Beam Therapeutics (NASDAQ:BEAM) received mixed analyst ratings, with a majority being bullish. The average 12-month price target increased by 11.22% to $55.83. Despite positive analyst sentiment, Beam faces financial challenges, including a 41.48% revenue decline and negative profitability metrics.
September 11, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Beam Therapeutics received mixed analyst ratings, with a majority being bullish. The average 12-month price target increased by 11.22% to $55.83. Despite positive analyst sentiment, Beam faces financial challenges, including a 41.48% revenue decline and negative profitability metrics.
The mixed analyst ratings, with a majority being bullish, suggest potential positive sentiment in the short term. However, the significant revenue decline and negative profitability metrics may offset this sentiment, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100